Thereafter , assessment of disease to be performed as per standard clinical practice. 7.4 Follow -up 7.4.1 3, 6, 9 and 12 months post first vaccination Patients should undergo the following assessments: • Research blood samples 3, 6 and 12 months (all +/ -1 week) post the first vaccination. • At the above time points, an evaluation of any AST-VAC2 related AEs will also be performed. Assessments can be performed as clinically indicated. • A further AE evaluation should be performed at 9 months post the first vaccinat ion also. This can be in the form of a phone call to the patient. • Any concomitant medications relevant to AST -VAC2 -related AEs should be recorded. All new and ongoing AST -VAC2 -related AEs should be followed up until resolution or stabilisation, even if the patient goes onto another anti -cancer treatment. SAEs considered related to AST -VAC2 are always reportable regardless of the time elapsed. 7.4.2 15, 18 and 21 month post first vaccination Evaluation of any new or ongoing AST -VAC2 -related AEs should be performed at 15, 18 and 21 months (i.e. quarterly).